A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans

Xenobiotica

Volumn 47, Issue 2, 2017, Pages 144-153

  Guerini, Elena ^a   Schadt, Simone ^a   Greig, Gerard ^a   Haas, Ruth ^a   Husser, Christophe ^a   Zell, Manfred ^a   Funk, Christoph ^a   Hartung, Thomas ^a   Gloge, Andreas ^a   Mallalieu, Navita L ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Roche Pharmaceutical Research and Early Development   (United States)

Author keywords

Basimglurant; bioavailability; intravenous; microtracer; oral; pharmacokinetic

Indexed keywords

6 BASIMGLURANT C 13; BASIMGLURANT; BASIMGLURANT C 12; BASIMGLURANT C 14; TRACER; UNCLASSIFIED DRUG; 2-CHLORO-4-(1-(4-FLUOROPHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL)PYRIDINE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; ATTENTION DISTURBANCE; BLOOD SAMPLING; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MICRODOSE; FECES ANALYSIS; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIQUID SCINTILLATION COUNTING; MALE; NORMAL HUMAN; RADIOACTIVITY; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE SAMPLING; AREA UNDER THE CURVE; HALF LIFE TIME; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; HALF-LIFE; HUMANS; IMIDAZOLES; PYRIDINES;

EID: 84968638542     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2016.1169334     Document Type: Article

References (21)

1. Berman RM, Narasimhan M, Sanacora G, et al. (2000). A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 47:332–7.
2. Chaki S, Ago Y, Palucha-Paniewiera A, et al. (2013). mGlu2/3 and mGlu5 receptors:potential targets for novel antidepressants. Neuropharmacology 66:40–52.
3. Connolly KR, Thase ME., (2012). Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 17:105–26.
4. Duman RS, Li N, Liu RJ, et al. (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62:35–41.
5. Garner RC., (2010). Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2:429–40.
6. Gobburu JV, Holford NH., (2001). Vz, the terminal phase volume:time for its terminal phase? J Biopharm Stat 11:373–5.
7. Ings RM., (2009). Microdosing:a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1:1293–305.
8. Krystal JH, Sanacora G, Duman RS., (2013). Rapid-acting glutamatergic antidepressants:the path to ketamine and beyond. Biol Psychiatry 73:1133–41.
9. Lappin G, Rowland M, Garner RC., (2006). The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2:419–27.
10. Lappin G, Wagner CC, Langer O, van de Merbel N., (2009). New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis 1:357–66.
11. Licznerski P, Duman RS., (2013). Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 251:33–50.
12. Maeda K, Sugiyama Y., (2011). Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev 63:532–8.
13. Manji HK, Quiroz JA, Sporn J, et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53:707–42.
14. Nemeroff CB., (2007). Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68:17–25.
15. Penner N, Klunk LJ, Prakash C., (2009). Human radiolabeled mass balance studies:objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203.
16. Roffey SJ, Obach RS, Gedge JI, Smith DA., (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metabol Rev 39:17–43.
17. Rubin GM, Waschek JA, Pond SM, et al. (1987). Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J Pharmacokinet Biopharm 15:615–31.
18. Sarapa N, Hsyu PH, Lappin G, Garner RC., (2005). The application of accelerator mass spectrometry to absolute bioavailability studies in humans:simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45:1198–205.
19. Zarate. CA, JrSingh JB, Carlson PJ, et al. (2006a). A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–64.
20. Zarate. CA, JrSingh JB, Quiroz JA, et al. (2006b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153–5.
21. Zarate. CA, Jr, Tohen M., (2004). Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 161:169–71.